Introduction {#s1}
============

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease characterized as chronic, progressive and fibrotic, and its clinical manifestation is progressive aggravation of dyspnea, restrictive ventilation dysfunction and gas-exchange disorder, hypoxemia and even respiratory failure ([@B2]). The chest high-resolution CT (HRCT) or lung histology of IPF is characteristic of usual interstitial pneumonia (UIP) ([@B37]). IPF is a rare disease, which is prone to the elderly. In Europe and North America, the incidence of IPF is about 2.8-9.3 per 100,000, and the epidemiological data in China is not much, but the incidence of IPF in recent years has increased significantly ([@B32]; [@B16]; [@B18]). IPF is currently incurable, and the clinical purpose is to delay the deterioration of lung function, improve the quality of life and delay the progress of the disease. At present, western medicine, such as antifibrotic drugs, has certain curative effect in the treatment of IPF, but due to the high price and some side effects, it is restricted in patient use ([@B23]). In recent years, the position of traditional Chinese medicine (TCM) in the treatment of IPF is becoming more and more important, and the clinical research and meta-analyses have shown that the herbal medicine treating IPF could improve the clinical symptoms, delay the reduction of the lung function, and improve the quality of life of the patients ([@B53]; [@B6]; [@B49]). Many experiments have shown that the herbal medicine has the effects of improving the pathological and pulmonary function of bleomycin-induced IPF rats ([@B5]; [@B54]).

Herbal medicine is the main treatment of TCM, the collocation of monarch herbs and minister herbs is adjusted according to the common pathogenesis of patients with further prescription to adapt to the different pathogenesis of IPF. DangGuiBuXue Decoction has the history of nearly 800 years, and is composed of two commonly used Chinese herbal medicines of Astragalus mongholicus Bunge, Radix Astragali (RA) and Angelica sinensis (Oliv.) Diels, Radix Angelicae Sinensis (RAS), and has the effects of benefiting vital energy and promoting blood circulation ([@B40]). At present, based on the association rules of the literature, the treatment of IPF with TCM is mainly related to benefiting vital energy and promoting blood circulation, among which RA and RAS are the most common herbs for invigorating qi and activating blood ([@B38]; [@B17]). There are many experiments on the treatment of IPF, which manifest RA and RAS can improve pulmonary fibrosis in animal model ([@B27]; [@B24]). Our recent research shows that RA and RAS in the treatment of IPF through the multi-target and multi-pathway were systematically discussed, which plays an important role in the clinical application ([@B55]).

At present, there are few clinical studies on the treatment of IPF with RA and RAS only, but many clinical studies on the treatment of IPF used herbal medicine included RA and RAS as the main components and have obtained good curative effect ([@B42]; [@B46]; [@B41]). There is no systematic evaluation report on the clinical efficacy of RA and RAS as the main components of herbal medicine in the treatment of IPF. The aim of this systematic review and meta-analysis was to critically evaluate the current evidence of effectiveness and safety on the use of RA and RAS in the treatment for patients with IPF.

Materials and Methods {#s2}
=====================

Data Sources and Search Strategy {#s2_1}
--------------------------------

We searched the main English and Chinese databases from the establishment of the database to October 30, 2019. PUBMED, EMBASE, Science Citation Index (SCI), Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature database (SinoMed), Chinese National Knowledge Infrastructure (CNKI), Wanfang Data and the Chongqing VIP database(CQVIP) were included.

The search term "pulmonary fibrosis" was combined with the following keywords respectively: "Astragali"; "Angelicae"; "DangGuiBuXue Decoction"; "DangGuiBuXue Tang"; "traditional Chinese Medicine"; "Chinese Medicine"; "herbal medicine". We also searched for these terms in titles and abstracts. When such data were not included in abstracts, if such data existed in the full text, the full-text paper was screened as well. We also checked references and citations of the identified studies manually to include other potentially eligible trials until no additional articles could be identified.

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

Inclusion criteria: (1) The study was designed as a randomized controlled trial (RCT); (2) The participants were in accordance with the diagnosis of IPF, which is in line with the Chinese Medical Association Respiratory Society issued guidelines for diagnosis and treatment or ATS/ERS/JRS/ALAT Clinical Practice Guideline; (3) Herbal medicine included RA and RAS was used in the experimental group; (4) The control group used conventional therapy without TCM therapy; (5) There were clear outcome measures.

Exclusion criteria: (1) Duplicated publications, the earlier published or the one with most complete information was included and the rest were excluded; (2) Animal experiments; (3) Case reports, reviews and abstracts; (4) Lack of data outcome measures to evaluate the effects.

Quality Assessment and Data Extraction {#s2_3}
--------------------------------------

Using the Jadad rating scale ([@B15]) and the Cochrane Reviewer\'s Handbook for guidelines, the quality and risk of bias of included studies were assessed ([@B15]).

The scores were obtained by evaluating a RCT with three items describing randomization (0-2 points), blinding (0-2 points), and dropouts and withdrawals (0-1 points). One point was given for each term if these terms were mentioned in the study. If the method to generate the sequence of randomization or the method of blinding was described and appropriate, then 1 additional point was given, whereas 1 point was deducted if it was inappropriate. The quality scale ranges from 0 to 5 points. Higher scores indicate better reporting. It was divided into low quality less than 3 and high quality greater than or equal to 3 ([@B19]).

We used the Cochrane classification of seven criteria to assess the risk of bias, which contained: random sequence generation, allocation concealment, patient blinding, assessor blinding, incomplete outcome data, selective outcome reporting and other risks of bias ([@B15]).

Two reviewers independently extracted the information of data, which included: the first author, year of publication, number of patients in each group, major composition of TCM prescriptions, methods of intervention on experimental group and control group and outcomes.

All authors consulted the disagreement about the detail of study until it was resolved by consensus.

Statistical Analyses {#s2_4}
--------------------

The Cochrane Collaboration\'s RevMan5.3 software was used for systematic review and meta-analysis. Continuous data were expressed as mean difference (MD) with 95% confidence interval (CI). Dichotomous data were expressed as odds ratio (OR) with 95% CI. A test of heterogeneity was assessed by the Q test (*P* value and *I²*), which describes the percentage of variability in the effect and estimates the contribution of heterogeneity rather than by chance ([@B13]; [@B14]). A significant Q-statistic (*P* \< 0.10) indicated heterogeneity across studies. Studies with an *I²* statistic of less than 50% are considered to have no heterogeneity and those with an *I²* statistic of equal or more than 50% are considered to have heterogeneity. If no significant heterogeneity was detected, the fixed effects model was used as the pooling method; otherwise, the random effect model was considered to be the appropriate choice. We perform the funnel plot to determine publication bias when more than 10 studies are included in a meta-analysis. All reported probabilities (*P* values) were two-sided, and *P*\< 0.05 was considered statistically significant.

Results {#s3}
=======

Research Selection {#s3_1}
------------------

A total of 4812 studies were retrieved through database searching and other sources. After removing duplication, 1424 studies had been retained. A total of 1346 obviously irrelevant studies were excluded after reading the title and the abstract, another 61 studies were excluded due to various reasons after reading the full text. Seventeen RCTs were included in the systematic evaluation ([@B42]; [@B46]; [@B41]; [@B8]; [@B50]; [@B45]; [@B4]; [@B48]; [@B29]; [@B57]; [@B20]; [@B7]; [@B28]; [@B30]; [@B51]; [@B12]; [@B35]). The literature screening process and results are shown in [**Figure 1**](#f1){ref-type="fig"}.

![Flow chart of the research selection process.](fphar-11-00415-g001){#f1}

Description of Included Studies {#s3_2}
-------------------------------

Seventeen eligible RCTs ([@B42]; [@B46]; [@B41]; [@B8]; [@B50]; [@B45]; [@B4]; [@B48]; [@B29]; [@B57]; [@B20]; [@B7]; [@B28]; [@B30]; [@B51]; [@B12]; [@B35]) were identified. Seventeen RCTs were all conducted in China and included 1211 patients. Two studies ([@B42]; [@B12]) were multicenter studies and others were single-center studies. One RCT ([@B35]) used the prescription of TCM only included RA and RAS and other RCTs used the prescription of TCM included RA and RAS as the main components. The control group included conventional western medicine treatment (CWMT), while prednisone tablets were used in a number of studies ([@B42]; [@B46]; [@B41]; [@B8]; [@B50]; [@B45]; [@B20]; [@B7]; [@B51]; [@B35]); prednisone tablets and cyclophosphamide tablets were used in three studies ([@B48]; [@B29]; [@B30]); acetylcysteine was used in two studies ([@B57]; [@B28]); one study ([@B12]) used placebo granules; one study ([@B4]) only mentioned the use of CWMT. Basic features of included studies are outlined in [**Table 1**](#T1){ref-type="table"}, the composition of TCM prescriptions used in experimental group of each study are outlined in [**Table 2**](#T2){ref-type="table"} and the quality control of TCM prescriptions are outlined in [**Table 3**](#T3){ref-type="table"}.

###### 

Summary of RCTs of RA and RAS for IPF.

  Study year\[ref\]        Country   Sample size (Experimental/Control)   Mean age (years) (Experimental/Control)   Experimental                                                                                       Control                                              Duration
  ------------------------ --------- ------------------------------------ ----------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------- -----------
  Sun XS 2005 ([@B42])     China     60(30/30)                            61.10 ± 12.88/66.67 ± 7.70                QiHong Decoction                                                                                   Prednisone tablet                                    3 months
  Wei GS 2007 ([@B46])     China     54(36/18)                            40-78(58.4)/38-74(55.2)                   CWMT + Prednisone tablet + TongFeiHuoXue Decoction                                                 CWMT + Prednisone tablet                             1 month
  Sun ZT 2008 ([@B41])     China     30(15/15)                            56.45 ± 7.88/56.88 ± 9.76                 Prednisone tablet + YiQiHuoXueSanJie Basic Prescription                                            Prednisone tablet                                    3 months
  Dong H 2010 ([@B8])      China     66(33/33)                            59.11 ± 11.18/57.7 ± 10.4                 Prednisone tablet + KangXianShuFei Granules                                                        Prednisone tablet                                    3 months
  Yang ZJ 2010 ([@B50])    China     40(20/20)                            60.4 ± 8.61/60.25 ± 8.72                  YiQiYangYin Prescription                                                                           Prednisone tablet                                    3 months
  Wang F 2011 ([@B45])     China     28(14/14)                            52.3 ± 3.6/54.5 ± 4. 6                    Prednisone tablet + KangXianShuFei Chinese Medicine                                                Prednisone tablet                                    6 months
  Chen P 2012 ([@B4])      China     50(25/25)                            55-72(63)/53-74(65)                       CWMT + HuaXianPoGu Decoction                                                                       CWMT                                                 3 months
  Wu HS 2012 ([@B48])      China     71(36/35)                            41-76(62.5)/42-79(63.4)                   CWMT + Prednisone tablet + Cyclophosphamide tablet + KangYangHuaXianRuanFei Magical Prescription   CWMT + Prednisone tablet + Cyclophosphamide tablet   6 months
  Meng Y 2016 ([@B29])     China     80(40/40)                            63.52/n.r.                                Prednisone tablet + Cyclophosphamide tablet + YiQiYangXue Chinese Medicine Decoction               Prednisone tablet + Cyclophosphamide tablet          2 months
  Zhao YD 2016 ([@B57])    China     120(60/60)                           55.17 ± 13.13/57.26 ± 10.14               CWMT + N-acetylcysteine tablet + BuFeiHuoXueHuaPi Prescription                                     CWMT + N-acetylcysteine tablet                       12 months
  Jiang WZ 2017 ([@B20])   China     80(40/40)                            65.58 ± 3.35/65.62 ± 3.40                 CWMT + Prednisone tablet + YiQiHuoTanZhuYu Chinese Medicine Prescription                           CWMT + Prednisone tablet                             40 days
  Miao G 2018 ([@B30])     China     80(40/40)                            67.4 ± 4.7/66.3 ± 4.8                     CWMT + Prednisone tablet + cyclophosphamide + YiQiYangYinSanJieHuaTan Prescription                 CWMT + Prednisone tablet + Cyclophosphamide tablet   2 months
  Yang QM 2018 ([@B51])    China     82(41/41)                            67.16 ± 7.84/67.56 ± 7.14                 CWMT + Prednisone tablet + YiQiHuoTanZhuYu Decoction                                               CWMT + Prednisone tablet                             1 month
  Ma Q 2018 ([@B28])       China     72(36/36)                            67.93 ± 8.49/69.17 ± 7.98                 CWMT + Echinocysteine effervescent tablet + BuYangHuanWu Decoction and LiuJunZi Decoction          CWMT + Acetylcysteine effervescent tablet            12 weeks
  Deng F 2018 ([@B7])      China     118(59/59)                           64.06 ± 7.82/63.21 ± 7.45                 CWMT + Prednisone tablet + HuangQiTaoHong Decoction                                                CWMT + Prednisone tablet                             3 months
  Guo SJ 2019 ([@B12])     China     130(65/65)                           59.45 ± 5.19/58.62 ± 5.02                 CWMT + QiZhuKangXian Granules                                                                      CWMT + placebo                                       48 weeks
  Peng YF 2019 ([@B35])    China     50(25/25)                            58.96 ± 8.73/59.80 ± 9. 34                CWMT + Prednisone tablet + QiGui Prescription                                                      CWMT + Prednisone tablet                             12 weeks

RCT, randomized controlled trial; RA, Radix Astragali; RAS, Radix Angelicae Sinensis; IPF, Idiopathic pulmonary fibrosis; CWMT, conventional western medicine treatment; n.r., not reported.

###### 

Composition of TCM prescriptions.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study year\[ref\]        TCM prescriptions                               Composition of TCM prescriptions                                        
  ------------------------ ----------------------------------------------- ------------------------------------- --------------------------------- ------------------
  Sun XS 2005 ([@B42])     QiHong Decoction                                **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Flos Carthami\                        Safflower\                        HongHua\
                                                                           Radix Curcumae\                       Curcuma Tuber\                    YuJin\
                                                                           Flos Inulae\                          Inula Flower\                     XuanFuHua\
                                                                           Semen Coicis\                         Job\'s Tears Seed\                YiYiRen\
                                                                           Radix Platycodi                       Balloon Flower Root               JieGeng

  Wei GS 2007 ([@B46])     TongFeiHuoXue Decoction                         **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Flos Lonicerae\                       Honeysuckle Flower\               JinYinHua\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Poria\                                Tuckahoe\                         FuLing\
                                                                           Semen Lepidii/Descurainiae\           Tingli Seed\                      TingLiZi\
                                                                           Fructus Aurantii\                     Bitter Orange\                    ZhiKe\
                                                                           Semen Persicae\                       Peach Kernel\                     TaoRen\
                                                                           Flos Inulae\                          Inula Flower\                     XuanFuHua\
                                                                           Flos Carthami                         Safflower                         HongHua

  Sun ZT 2008 ([@B41])     YiQiHuoXueSanJie Basic Prescription             **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Rhizoma Curcumae (Zedoariae)\         Curcuma Rhizome\                  EZhu\
                                                                           Radix Codonopsis\                     Codonopsis Root\                  DangShen\
                                                                           Bulbus Fritillariae Cirrhosae\        Fritillaria Bulb\                 ChuanBeiMu\
                                                                           Radix Scutellariae\                   Baical Skullcap Root\             HuangQin\
                                                                           Radix Curcumae                        Curcuma Tuber                     YuJin

  Dong H 2010 ([@B8])      KangXianShuFei Granules                         **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Codonopsis\                     Codonopsis Root\                  DangShen\
                                                                           Radix Scutellariae\                   Baical Skullcap Root\             HuangQin\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Radix Adenophorae/Glehniae\           Four Leaf Lady-Bell Root\         ShaShen\
                                                                           Radix Paeoniae Alba\                  White Peony Root\                 BaiShao\
                                                                           Semen Lepidii/Descurainiae\           Tingli Seed\                      TingLiZi\
                                                                           Herba Houttuyniae\                    Houttuynia\                       YuXingCao\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Semen Armeniacae\                     Bitter Apricot Kernel\            XingRen\
                                                                           Fructus Trichosanthis                 Trichosanthes Fruit               GuaLou

  Yang ZJ 2010 ([@B50])    YiQiYangYin Prescription                        **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Rhizoma Atractylodis Macrocephalae\   Atractylodis Rhizome\             BaiZhu\
                                                                           Radix Saposhnikoviae\                 Saposhnikoviae Root\              FangFeng\
                                                                           Radix Pseudostellariae\               Pseudostellaria Root\             TaiZiShen\
                                                                           Radix Ophiopogonis\                   Ophiopogon Tuber\                 MaiDong\
                                                                           Radix Platycodi\                      Balloon Flower Root\              JieGeng\
                                                                           Semen Armeniacae\                     Bitter Apricot Kernel\            XingRen\
                                                                           Bulbus Fritillariae Thunbergii\       Zhejiang Fritillaria Bulb\        ZheBeiMu\
                                                                           Rhizoma Anemarrhenae\                 Anemarrhena Rhizome\              ZhiMu\
                                                                           Caulis Perillae\                      Perilla Stem\                     ZiSuGeng\
                                                                           Bulbus Lilii\                         Lily Bulb\                        BaiHe\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Wang F 2011 ([@B45])     KangXianShuFei Chinese Medicine                 **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Codonopsis\                     Codonopsis Root\                  DangShen\
                                                                           Radix Scutellariae\                   Baical Skullcap Root\             HuangQin\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Radix Adenophorae/Glehniae\           Four Leaf Lady-Bell Root\         ShaShen\
                                                                           Radix Paeoniae Alba\                  White Peony Root\                 BaiShao\
                                                                           Semen Lepidii/Descurainiae\           Tingli Seed\                      TingLiZi\
                                                                           Herba Houttuyniae\                    Houttuynia\                       YuXingCao\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Semen Armeniacae\                     Bitter Apricot Kernel\            XingRen\
                                                                           Fructus Trichosanthis                 Trichosanthes Fruit               GuaLou

  Chen P 2012 ([@B4])      HuaXianPoGu Decoction                           **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Rehmanniae\                     Rehmannia Root\                   DiHuang\
                                                                           Herba Epimedii\                       Epimedium\                        YinYangHuo\
                                                                           Fructus Forsythiae\                   Forsythia Fruit\                  LianQiao\
                                                                           Radix Platycodi\                      Balloon Flower Root\              JieGeng\
                                                                           Fructus Aurantii\                     Bitter Orange\                    ZhiKe\
                                                                           Semen Armeniacae\                     Bitter Apricot Kernel\            XingRen\
                                                                           Fructus Schisandrae\                  Schisandra Fruit\                 WuWeiZi\
                                                                           Radix Paeoniae Alba\                  White Peony Root\                 BaiShao\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Rhizoma Arisaematis\                  Arisaema Rhizome\                 TianNanXing\
                                                                           Bulbus Fritillariae Cirrhosae\        Fritillaria Bulb\                 ChuanBeiMu\
                                                                           Pericarpium Citri Reticulatae\        Tangerine Peel\                   ChenPi\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Semen Persicae\                       Peach Kernel\                     TaoRen\
                                                                           Pheretima\                            Earthworm\                        DiLong\
                                                                           Poria\                                Tuckahoe\                         FuLing\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Wu HS 2012 ([@B48])      KangYangHuaXianRuanFei Magical Prescription     **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Scutellariae\                   Baical Skullcap Root\             HuangQin\
                                                                           Rhizoma Atractylodis Macrocephalae\   Atractylodis Rhizome\             BaiZhu\
                                                                           Cordyceps\                            Chinese Caterpillar Fungus\       DongChongXiaCao\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Hirudo\                               Leech\                            ShuiZhi\
                                                                           Pheretima\                            Earthworm\                        DiLong\
                                                                           Rhizoma Polygoni Cuspidati\           Bushy Knotweed Rhizome\           HuZhang\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Bulbus Fritillariae Thunbergii\       Zhejiang Fritillaria Bulb\        ZheBeiMu\
                                                                           Radix Ginseng\                        Ginseng Root\                     RenShen\
                                                                           Herba Epimedii\                       Epimedium\                        YinYangHuo\
                                                                           Fructus Ligustri Lucidi\              Glossy Privet Berry\              NvZhenZi\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Meng Y 2016 ([@B29])     YiQiYangXue Chinese Medicine Decoction          **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Codonopsis\                     Codonopsis Root\                  DangShen\
                                                                           Rhizoma Imperatae\                    Woolly Grass Rhizome\             BaiMaoGen\
                                                                           Radix Adenophorae\                    Adenophora (Nan)\                 NanShaShen\
                                                                           Radix Glehniae\                       Glehnia Root (Bei)\               BeiShaShen\
                                                                           Radix Scrophulariae\                  Scrophularia\                     XuanShen\
                                                                           Rhizoma Phragmitis\                   Reed Rhizome\                     LuGen\
                                                                           Radix Paeoniae Alba\                  White Peony Root\                 BaiShao\
                                                                           Semen Armeniacae\                     Bitter Apricot Kernel\            XingRen\
                                                                           Bulbus Fritillariae Thunbergii\       Zhejiang Fritillaria Bulb\        ZheBeiMu\
                                                                           Radix Glycyrrhizae\                   Licorice Root\                    GanCao\
                                                                           Radix Stemonae\                       Stemona Root\                     BaiBu\
                                                                           Fructus Jujube\                       Jujube Berry\                     DaZao\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Carapax Trionycis                     Chinese Soft-Shell Turtle Shell   BieJia

  Zhao YD 2016 ([@B57])    BuFeiHuoXueHuaPi Prescription                   **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Codonopsis\                     Codonopsis Root\                  DangShen\
                                                                           Flos Carthami\                        Safflower\                        HongHua\
                                                                           Bulbus Fritillariae Thunbergii\       Zhejiang Fritillaria Bulb\        ZheBeiMu\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Bulbus Lilii\                         Lily Bulb\                        BaiHe\
                                                                           Semen Ginkgo\                         Ginkgo Nut\                       BaiGuo\
                                                                           Fructus Aurantii\                     Bitter Orange\                    ZhiKe\
                                                                           Fructus Perillae\                     Perilla Fruit\                    SuZi\
                                                                           Bulbus Allii Macrostemi               Chinese Garlic                    XieBai

  Jiang WZ 2017 ([@B20])   YiQiHuoTanZhuYu Chinese Medicine Prescription   **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Glehniae\                       Glehnia Root (Bei)\               BeiShaShen\
                                                                           Radix Rehmanniae\                     Rehmannia Root\                   DiHuang\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Fructus Schisandrae\                  Schisandra Fruit\                 WuWeiZi\
                                                                           Radix Ophiopogonis\                   Ophiopogon Tuber\                 MaiDong\
                                                                           Pericarpium Citri Reticulatae\        Tangerine Peel\                   ChenPi\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Miao G 2018 ([@B30])     YiQiYangYinSanJieHuaTan Prescription            **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Ophiopogonis\                   Ophiopogon Tuber\                 MaiDong\
                                                                           Radix Glehniae\                       Glehnia Root (Bei)\               BeiShaShen\
                                                                           Semen Persicae\                       Peach Kernel\                     TaoRen\
                                                                           Radix Codonopsis\                     Codonopsis Root\                  DangShen\
                                                                           Pseudobulbus Cremastrae/Pleiones\     Cremastra/Pleione\                ShanCiGu\
                                                                           Rhizoma Curcumae (Zedoariae)\         Curcuma Rhizome\                  EZhu\
                                                                           Rhizoma Sparganii\                    Burr-Reed Rhizome\                SanLeng\
                                                                           Radix Salviae Miltiorrhizae           Red Sage Root                     DanShen

  Yang QM 2018 ([@B51])    YiQiHuoTanZhuYu Decoction                       **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Glehniae\                       Glehnia Root (Bei)\               BeiShaShen\
                                                                           Radix Rehmanniae\                     Rehmannia Root\                   DiHuang\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Radix Ophiopogonis\                   Ophiopogon Tuber\                 MaiDong\
                                                                           Fructus Schisandrae\                  Schisandra Fruit\                 WuWeiZi\
                                                                           Pericarpium Citri Reticulatae\        Tangerine Peel\                   ChenPi\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Ma Q 2018 ([@B28])       BuYangHuanWu Decoction and LiuJunZi Decoction   **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Paeoniae Rubra\                 Red Peony Root\                   ChiShao\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Pheretima\                            Earthworm\                        DiLong\
                                                                           Rhizoma Atractylodis Macrocephalae\   Atractylodis Rhizome\             BaiZhu\
                                                                           Radix Saposhnikoviae\                 Saposhnikoviae Root\              FangFeng\
                                                                           Poria\                                Tuckahoe\                         FuLing\
                                                                           DangShen\                             Codonopsis Root\                  DangShen\
                                                                           Pericarpium Citri Reticulatae\        Tangerine Peel\                   ChenPi\
                                                                           Rhizoma Pinelliae\                    Pinellia Rhizome\                 BanXia\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Deng F 2018 ([@B7])      HuangQiTaoHong Decoction                        **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Radix Salviae Miltiorrhizae\          Red Sage Root\                    DanShen\
                                                                           Rhizoma Chuanxiong\                   Szechwan Lovage Rhizome\          ChuanXiong\
                                                                           Semen Persicae\                       Peach Kernel\                     TaoRen\
                                                                           Flos Carthami                         Safflower                         HongHua

  Guo SJ 2019 ([@B12])     QiZhuKangXian Granules                          **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**\         **Chinese Angelica Root**\        **DangGui**\
                                                                           Rhizoma Curcumae (Zedoariae)\         Curcuma Rhizome\                  EZhu\
                                                                           Fructus Corni\                        Asiatic Cornelian Cherry Fruit\   ShanZhuYu\
                                                                           Radix Asteris\                        Tatarian Aster Root\              ZiWan\
                                                                           Bulbus Fritillariae Thunbergii\       Zhejiang Fritillaria Bulb\        ZheBeiMu\
                                                                           Radix Scutellariae\                   Baical Skullcap Root\             HuangQin\
                                                                           Radix Glycyrrhizae                    Licorice Root                     GanCao

  Peng YF 2019 ([@B35])    QiGui Prescription                              **Radix Astragali**\                  **Astragalus Root**\              **HuangQi**\
                                                                           **Radix Angelicae Sinensis**          **Chinese Angelica Root**         **DangGui**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Quality control of TCM prescriptions.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study year\[ref\]        TCM prescriptions                               Source                                                                                 Species, concentration            Quality control reported                      Chemical analysis reported
  ------------------------ ----------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------- --------------------------------------------- ---------------------------------
  Sun XS 2005 ([@B42])     QiHong Decoction                                East Hospital of Beijing University of Chinese Medicine, Dongzhimen Hospital           Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Wei GS 2007 ([@B46])     TongFeiHuoXue Decoction                         Affiliated Hospital of Shaanxi College of TCM                                          Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 12g\                                                  
                                                                                                                                                                  et al                                                                           

  Sun ZT 2008 ([@B41])     YiQiHuoXueSanJie Basic Prescription             The Second Hospital Affiliated to the Tianjin University of TCM                        Radix Astragali, 20g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Dong H 2010 ([@B8])      KangXianShuFei Granules                         Tai\'an TCM Hospital                                                                   Radix Astragali, 10g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 10g\                                                  
                                                                                                                                                                  et al                                                                           

  Yang ZJ 2010 ([@B50])    YiQiYangYin Prescription                        QianFoshan Hospital of Shandong Province                                               Radix Astragali, n.r.\            n.r.                                          Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, n.r.\                                                 
                                                                                                                                                                  et al                                                                           

  Wang F 2011 ([@B45])     KangXianShuFei Chinese Medicine                 First affiliated Hospital of Guangzhou Medical College, Guangdong Province             Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Chen P 2012 ([@B4])      HuaXianPoGu Decoction                           The first affiliated Hospital of Guangxi University of TCM                             Radix Astragali, n.r.\            n.r.                                          Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, n.r.\                                                 
                                                                                                                                                                  et al                                                                           

  Wu HS 2012 ([@B48])      KangYangHuaXianRuanFei Magical Prescription     Jiuquan people\'s Hospital                                                             Radix Astragali, 18g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 9g\                                                   
                                                                                                                                                                  et al                                                                           

  Meng Y 2016 ([@B29])     YiQiYangXue Chinese Medicine Decoction          Henan traditional Chinese Medicine Hospital                                            Radix Astragali, 15-60g\          Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 9g\                                                   
                                                                                                                                                                  et al                                                                           

  Zhao YD 2016 ([@B57])    BuFeiHuoXueHuaPi Prescription                   The first affiliated Hospital of Dalian Medical University                             Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 10g\                                                  
                                                                                                                                                                  et al                                                                           

  Jiang WZ 2017 ([@B20])   YiQiHuoTanZhuYu Chinese Medicine Prescription   Weifang traditional Chinese Medicine Hospital                                          Radix Astragali, 20g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 10g\                                                  
                                                                                                                                                                  et al                                                                           

  Miao G 2018 ([@B30])     YiQiYangYinSanJieHuaTan Prescription            Traditional Chinese Medicine Hospital of Luoding City, Guangdong Province              Radix Astragali, 15g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Yang QM 2018 ([@B51])    YiQiHuoTanZhuYu Decoction                       The first affiliated Hospital of Henan University of traditional Chinese Medicine      Radix Astragali, 15g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Ma Q 2018 ([@B28])       BuYangHuanWu Decoction and LiuJunZi Decoction   Affiliated Hospital of Gansu University of traditional Chinese Medicine                Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Deng F 2018 ([@B7])      HuangQiTaoHong Decoction                        People\'s Hospital of Hanchuan City, Hubei Province                                    Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 15g\                                                  
                                                                                                                                                                  et al                                                                           

  Guo SJ 2019 ([@B12])     QiZhuKangXian Granules                          The second affiliated Hospital of Tianjin University of traditional Chinese Medicine   Radix Astragali\                  Prepared according to Chinese pharmacopeia\   Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis\         Batch number: 20130708, 20150315              
                                                                                                                                                                  et al                                                                           

  Peng YF 2019 ([@B35])    QiGui Prescription                              Central South Hospital of Wuhan University                                             Radix Astragali, 30g\             Prepared according to Chinese pharmacopeia    Based on previous HPLC research
                                                                                                                                                                  Radix Angelicae Sinensis, 6g                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TCM, traditional Chinese medicine; HPLC, high-performance liquid chromatography; n.r., not reported.

Methodological Quality {#s3_3}
----------------------

Five RCTs ([@B41]; [@B28]; [@B30]; [@B12]; [@B35]) employed adequate methods of random sequence generation; one RCT ([@B12]) introduced allocation concealment; one RCT ([@B12]) introduced blindness and used placebo, one RCT ([@B51]) used double blindness, but did not describe it specifically; two RCTs ([@B45]; [@B28]) had inaccurate outcome data; and all studies were unable to know if there were selective reports ([**Figures S1**](#SM1){ref-type="supplementary-material"} and [**S2**](#SM1){ref-type="supplementary-material"}, [**Table 4**](#T4){ref-type="table"}).

###### 

Risk of bias and quality of included RCTs.

  Study year\[ref\]        Random sequence generation   Allocation concealment   Blinding of patient   Blinding of assessor   Incomplete outcome data   Selective reporting   Other bias   Jadad score
  ------------------------ ---------------------------- ------------------------ --------------------- ---------------------- ------------------------- --------------------- ------------ -------------
  Sun XS 2005 ([@B42])     U                            U                        H                     H                      L                         U                     L            2
  Wei GS 2007 ([@B46])     U                            U                        H                     H                      L                         U                     L            1
  Sun ZT 2008 ([@B41])     L                            U                        H                     H                      L                         U                     L            3
  Dong H 2010 ([@B8])      U                            U                        H                     H                      L                         U                     L            1
  Yang ZJ 2010 ([@B50])    U                            U                        H                     H                      L                         U                     L            2
  Wang F 2011 ([@B45])     U                            U                        H                     H                      H                         U                     H            1
  Chen P 2012 ([@B4])      U                            U                        H                     H                      L                         U                     L            1
  Wu HS 2012 ([@B48])      U                            U                        H                     H                      L                         U                     L            1
  Meng Y 2016 ([@B29])     U                            U                        H                     H                      L                         U                     L            1
  Zhao YD 2016 ([@B57])    U                            U                        H                     H                      L                         U                     L            1
  Jiang WZ 2017 ([@B20])   U                            U                        H                     H                      L                         U                     L            1
  Miao G 2018 ([@B30])     L                            U                        H                     H                      L                         U                     L            2
  Yang QM 2018 ([@B51])    U                            U                        U                     U                      L                         U                     L            2
  Ma Q 2018 ([@B28])       L                            U                        H                     H                      H                         U                     H            3
  Deng F 2018 ([@B7])      U                            U                        H                     H                      L                         U                     L            1
  Guo SJ 2019 ([@B12])     L                            L                        L                     L                      L                         U                     L            5
  Peng YF 2019 ([@B35])    L                            U                        H                     H                      L                         U                     L            3

RCT, randomized controlled trial; L, low risk of bias; H, high risk of bias; U, Unclear (uncertain risk of bias).

The Jadad rating score was assigned from 1 to 5 points. Most studies had poor quality. The Jadad rating score was 5 points in one RCT ([@B12]), 3 points in three RCTs ([@B41]; [@B28]; [@B35]), 2 points in four RCTs ([@B42]; [@B50]; [@B30]; [@B51]; [@B12]) and 1 point in the other nine RCTs ([@B46]; [@B8]; [@B45]; [@B4]; [@B48]; [@B29]; [@B57]; [@B20]; [@B7]) ([**Table 4**](#T4){ref-type="table"}).

Outcomes {#s3_4}
--------

Fifteen RCTs ([@B42]; [@B46]; [@B41]; [@B8]; [@B50]; [@B45]; [@B4]; [@B29]; [@B57]; [@B20]; [@B7]; [@B28]; [@B51]; [@B12]; [@B35]) compared the total effective rate of clinical effect and three RCTs ([@B50]; [@B28]; [@B12]) compared the TCM syndrome effective rate of clinical effect.

Two RCTs ([@B57]; [@B12]) compared force vital capacity (FVC), five RCTs ([@B8]; [@B48]; [@B29]; [@B7]; [@B12]) compared FVC% predicted (FVC% pred) of lung function, one RCTs ([@B28]) compared total lung capacity (TLC), two RCTs ([@B42]; [@B4]) compared TLC% predicted (TLC% pred), four RCTs ([@B46]; [@B57]; [@B28]; [@B12]) compared carbon monoxide diffusing capacity (DLCO), seven RCTs ([@B42]; [@B8]; [@B4]; [@B48]; [@B7]; [@B12]; [@B35]) compared DLCO% predicted (DLCO% pred), three RCTs ([@B46]; [@B20]; [@B28]) compared vital capacity (VC) of lung function, two RCTs ([@B4]; [@B35]) compared VC% predicted (VC% pred), one RCTs ([@B57]) compared forced expiratory volume in one second (FEV1), two RCTs ([@B8]; [@B29]) compared FEV1% predicted (FEV1% pred), two RCTs ([@B57]; [@B30]) compared FEV1/FVC and one RCTs ([@B12]) compared ΔFVC.

Five RCTs ([@B29]; [@B20]; [@B30]; [@B51]; [@B35]) compared six minute walking distance (6MWD), four RCTs ([@B41]; [@B48]; [@B12]; [@B35]) compared total score of St. George\'s Respiratory Questionnaire (SGRQ) score, three RCTs ([@B41]; [@B48]; [@B12]; [@B35]) compared symptoms score of SGRQ score, three RCTs ([@B41]; [@B48]; [@B12]) compared activity limitation score of SGRQ scores and three RCTs ([@B41]; [@B48]; [@B12]) compared impact score of SGRQ score and two RCTs ([@B29]; [@B30]) compared Borg scale questionnaire scores.

Ten RCTs ([@B42]; [@B46]; [@B8]; [@B50]; [@B45]; [@B4]; [@B48]; [@B20]; [@B7]; [@B35]) compared arterial oxygen partial pressure (PaO~2~) of arterial blood gas, four RCTs ([@B29]; [@B28]; [@B30]; [@B35]) compared arterial oxygen saturation (SaO~2~) of arterial blood gas and one RCT ([@B29]; [@B28]; [@B30]; [@B35]) compared arterial carbon dioxide partial pressure (PaCO~2~) of arterial blood gas. The arterial blood gas data in one RCT ([@B45]) were inaccurate.

Three RCTs ([@B41]; [@B4]; [@B35]) compared transforming growth factor (TGF)-β1 of serum cytokines, two RCTs ([@B42]; [@B35]) compared tumor necrosis factor (TNF)-α of serum cytokines and one RCTs ([@B42]) compared interleukin (IL)-8 of serum cytokines.

Five RCTs ([@B42]; [@B28]; [@B51]; [@B12]; [@B35]) compared total syndrome score of TCM, five RCTs ([@B42]; [@B50]; [@B29]; [@B28]; [@B30]) compared cough syndrome score of TCM, five RCTs ([@B42]; [@B50]; [@B29]; [@B30]; [@B28]) compared wheezing syndrome score of TCM, three RCTs ([@B42]; [@B50]; [@B28]) compared shortness of breath syndrome score of TCM, three RCTs ([@B50]; [@B29]; [@B30]) compared fatigue syndrome score of TCM, two RCTs ([@B50]; [@B29]) compared thirst syndrome score of TCM, two RCTs ([@B29]; [@B30]) compared coated tongue syndrome score of TCM, two studies ([@B29]; [@B30]) compared pulse manifestation syndrome score of TCM, two studies compared ([@B42]; [@B28]) phlegm syndrome score of TCM, two studies ([@B42]; [@B28]) compared velcro rale syndrome score of TCM, one RCT ([@B42]) compared feel suffocated syndrome score of TCM, one RCT ([@B42]) compared chest stuffiness syndrome score of TCM, one RCT ([@B50]) compared anepithymia syndrome score of TCM, one RCT ([@B29]) compared sweating syndrome score of TCM, one RCT ([@B28]) compared cyanosis syndrome score of TCM and one RCT ([@B28]) compared clubbed-finger syndrome score of TCM.

Two RCTs ([@B8]; [@B28]) compared HRCT score, one RCT ([@B50]) compared main symptom score (dyspnea, dry cough, chest pain, breathing rate, chest rale, X ratios, lung function, pulmonary diffusion function and arterial oxygen), one RCT ([@B28]) compared 6MWD scores, one RCT ([@B7]) compared insulin like growth factors (IGF)-1 and insulin like growth factor binding protein (IGFBP)-4 of bronchoalveolar lavage fluid (BALF), one RCT ([@B7]) compared HRCT effective rate, one RCT ([@B50]) compared effective rate of quality of life, two RCTs ([@B42]; [@B50]) compared pulmonary reinfection rate, one RCT ([@B50]) compared antibiotic utilization rate, one RCT ([@B28]) compared mMRC dyspnea scale, but its dada were inaccurate.

Adverse reactions were mentioned in the seven studies ([@B42]; [@B46]; [@B50]; [@B29]; [@B28]; [@B12]; [@B35]), and the other studies did not mention whether there were adverse reactions.

The main outcomes and results are outlined in [**Table 5**](#T5){ref-type="table"}.

###### 

Main outcomes of included RCTs.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Study year\[ref\]        Main outcomes                           Main results (Effect size)       Adverse events
  ------------------------ --------------------------------------- -------------------------------- ------------------------------------------------------
  Sun XS 2005 ([@B42])     1\) Clinical efficacy\                  OR, 3.60 \[1.22, 10.64\]\        Experimental: No adverse reactions\
                           Total effective rate\                   MD, 2.06 \[-6.85, 10.97\]\       Control: Serum transaminase elevated(n= 4)
                           2) Pulmonary function tests tests\      MD, -1.43 \[-9.79, 6.93\]\       
                           TLC% pred\                              MD, 5.66 \[0.77, 10.55\]\        
                           DLCO% pred\                             MD, -3.23 \[-40.15, 33.69\]\     
                           3) Arterial blood gas\                  MD, -3.46 \[-8.40, 1.48\]\       
                           PaO~2~\                                 MD, -5.70 \[-9.18, -2.22\]\      
                           4) Serum cytokines\                     MD, -2.10 \[-2.78, -1.42\]\      
                           IL-8\                                   MD, -1.54 \[-2.37, -0.71\]\      
                           TNF-α\                                  MD, -0.78 \[-1.50, -0.06\]\      
                           4) Syndrome score of TCM\               MD, -0.22 \[-0.95, 0.51\]\       
                           Total syndrome score\                   MD, -0.37 \[-0.73, -0.01\]\      
                           Wheezing\                               MD, 0.37 \[0.01, 0.73\]\         
                           Feel suffocated\                        MD, -0.89 \[-1.58, -0.20\]\      
                           Chest stuffiness\                       OR, 2.40 \[0.58, 9.93\]\         
                           Short of breath\                        OR, 0.07 \[0.00, 1.24\]          
                           Cough\                                                                   
                           Phlegm\                                                                  
                           Velcro rale\                                                             
                           5) HRCT effective rate\                                                  
                           6) Pulmonary reinfection rate                                            

  Wei GS 2007 ([@B46])     1\) Clinical efficacy\                  OR, 2.07 \[0.58, 7.46\]\         No adverse reactions
                           Total effective rate\                   MD, 0.37 \[-0.73, 1.47\]\        
                           2) Pulmonary function tests\            MD, 0.08 \[-0.10, 0.26\]\        
                           DLCO\                                   MD, 0.37 \[-3.28, 4.02\]         
                           VC\                                                                      
                           3) Arterial blood gas\                                                   
                           PaO~2~                                                                   

  Sun ZT 2008 ([@B41])     1\) Clinical efficacy\                  OR, 3.25 \[0.52, 20.37\]\        n.r.
                           Total effective rate\                   MD, -5.00 \[-14.83, 4.83\]\      
                           2) SGRQ score\                          MD, -8.00 \[-16.70, 0.70\]\      
                           Total score\                            MD, -5.00 \[-15.26, 5.26\]\      
                           Symptoms score\                         MD, -7.00 \[-15.23, 1.23\]\      
                           Activity limitation score\              MD, 0.82 \[-0.06, 1.70\]         
                           Impact score\                                                            
                           3) serum cytokines\                                                      
                           TGF-β1                                                                   

  Dong H 2010 ([@B8])      1\) Clinical efficacy\                  OR, 12.93 \[0.69, 244.05\]\      n.r.
                           Total effective rate\                   MD, 9.00 \[4.66, 13.34\]\        
                           2) Pulmonary function tests\            MD, 9.00 \[5.85, 12.15\]\        
                           FVC% pred\                              MD, 7.00 \[3.59, 10.41\]\        
                           DLCO% pred\                             MD, 9.00 \[4.89, 13.11\]\        
                           FEV1% pred\                             MD, -1.98 \[-3.80, -0.16\]       
                           3) Arterial blood gas\                                                   
                           PaO~2~\                                                                  
                           3) HRCT score                                                            

  Yang ZJ 2010 ([@B50])    1\) Clinical efficacy\                  OR, 8.14 \[0.88, 75.48\]\        Experimental: No adverse reactions\
                           Total effective rate\                   OR, 8.14 \[0.88, 75.48\]\        Control: venous blood glucose increased (n= 3)
                           TCM syndrome effective\                 MD, 2.20 \[0.71, 3.69\]\         
                           2) Arterial blood gas\                  MD, -0.40 \[-1.16, 0.36\]\       
                           PaO~2~\                                 MD, -1.00 \[-1.56, -0.44\]\      
                           3) Syndrome score of TCM\               MD, -0.60 \[-1.19, -0.01\]\      
                           Wheezing\                               MD, -1.00 \[-1.85, -0.15\]\      
                           Cough\                                  MD, -0.60 \[-1.19, -0.01\]\      
                           Fatigue\                                MD, -1.00 \[-1.67, -0.33\]\      
                           Short of breath\                        MD, -0.25 \[-1.78, 1.28\]\       
                           Anepithymia\                            MD, -0.80 \[-1.48, -0.12\]\      
                           Thirst\                                 MD, -0.20 \[-1.07, 0.67\]\       
                           4) Main symptom score\                  MD, -0.20 \[-1.17, 0.77\]\       
                           Dyspnea\                                MD, -0.60 \[-1.32, 0.12\]\       
                           Dry cough\                              MD, -0.50 \[-2.42, 1.42\]\       
                           Chest pain\                             MD, -1.00 \[-3.01, 1.01\]\       
                           Breathing rate\                         MD, -0.50 \[-2.11, 1.11\]\       
                           Chest rale\                             MD, -1.50 \[-3.63, 0.63\]\       
                           X ratios\                               OR, 6.33 \[0.67, 60.16\]\        
                           Pulmonary function tests\               OR, 0.22 \[0.06, 0.86\]\         
                           pulmonary diffusion function\           OR, 0.22 \[0.06, 0.86\]          
                           Arterial oxygen\                                                         
                           5) Effective rate of quality of life\                                    
                           6) Pulmonary reinfection rate\                                           
                           7) Antibiotic utilization rate                                           

  Wang F 2011 ([@B45])     1\) Clinical efficacy\                  OR, 4.50 \[0.72, 28.15\]\        n.r.
                           Total effective rate\                   Inaccurate data\                 
                           4) arterial blood gas\                  Inaccurate data                  
                           PaO~2~\                                                                  
                           PaCO~2~                                                                  

  Chen P 2012 ([@B4])      1\) Clinical efficacy\                  OR, 5.41 \[1.02, 28.79\]\        n.r.
                           Total effective rate\                   MD, 7.09 \[2.12, 12.06\]\        
                           2) Pulmonary function tests\            MD, 5.74 \[1.32, 10.16\]\        
                           TLC% pred\                              MD, 5.85 \[1.37, 10.33\]\        
                           DLCO% pred\                             MD, 6.51 \[0.98, 12.04\]\        
                           VC% pred\                               MD, -0.41 \[-1.50, 0.68\]        
                           3) Arterial blood gas\                                                   
                           PaO~2~\                                                                  
                           4) Serum cytokines\                                                      
                           TGF-β1                                                                   

  Wu HS 2012 ([@B48])      1\) Pulmonary function tests\           MD, 8.20 \[6.34, 10.06\]\        n.r.
                           FVC% pred\                              MD, 7.53 \[4.38, 10.68\]\        
                           DLCO% pred\                             MD, -10.00 \[-15.87, -4.13\]\    
                           2) SGRQ score\                          MD, -9.00 \[-14.12, -3.88\]\     
                           Total score\                            MD, -12.00 \[-17.35, -6.65\]\    
                           Symptoms score\                         MD, 3.00 \[-2.60, 8.60\]\        
                           Activity limitation score\              MD, 5.87 \[2.18, 9.56\]          
                           Impact score\                                                            
                           3) Arterial blood gas\                                                   
                           PaO~2~                                                                   

  Meng Y 2016 ([@B29])     1\) Clinical efficacy\                  OR, 2.90 \[0.53, 16.03\]\        Experimental: venous blood glucose increased (n= 1)\
                           Total effective rate\                   MD, 4.83 \[0.59, 9.07\]\         Control: venous blood glucose increased (n= 2)\
                           2) Pulmonary function tests\            MD, 3.10 \[-1.22, 7.42\]\        blood pressure elevated (n= 1)\
                           FVC% pred\                              MD, 16.27 \[-45.24, 77.78\]\     Serum transaminase elevated (n= 1)
                           FEV1% pred\                             MD, -0.66 \[-1.05, -0.27\]\      
                           3) 6MWD\                                MD, 1.19 \[0.26, 2.12\]\         
                           5) Borg scale questionnaire\            MD, -0.97 \[-1.46, -0.48\]\      
                           5) Arterial blood gas\                  MD, -0.66 \[-1.23, -0.09\]\      
                           SaO~2~\                                 MD, -0.28 \[-0.79, 0.23\]\       
                           6) Syndrome score of TCM\               MD, -1.01 \[-1.53, -0.49\]\      
                           Wheezing\                               MD, -0.68 \[-1.21, -0.15\]\      
                           Cough\                                  MD, -0.77 \[-1.35, -0.19\]\      
                           Sweating\                               MD, -0.82 \[-1.29, -0.35\]       
                           Fatigue\                                                                 
                           Thirst\                                                                  
                           Coated tongue\                                                           
                           Pulse manifestation                                                      

  Zhao YD 2016 ([@B57])    1\) Clinical efficacy\                  OR, 15.62 \[3.46, 70.41\]\       n.r.
                           Total effective rate\                   MD, 0.76 \[0.51, 1.01\]\         
                           2) Pulmonary function tests\            MD, 5.03 \[5.00, 5.06\]\         
                           FVC\                                    MD, 0.26 \[0.09, 0.43\]\         
                           DLCO\                                   MD, 5.90 \[3.47, 8.33\]          
                           FEV1\                                                                    
                           FEV1/FVC                                                                 

  Jiang WZ 2017 ([@B20])   1\) Clinical efficacy\                  OR, 3.27 \[1.21, 8.84\]\         n.r.
                           Total effective rate\                   MD, 0.30 \[0.27, 0.33\]\         
                           2) Pulmonary function tests\            MD, 29.63 \[27.67, 31.59\]\      
                           VC\                                     MD, 8.20 \[4.44, 11.96\]         
                           3) 6MWD\                                                                 
                           4) Arterial blood gas\                                                   
                           PaO~2~                                                                   

  Miao G 2018 ([@B30])     1\) Pulmonary function tests\           MD, 5.72 \[2.34, 9.10\]\         n.r.
                           FEV1/FVC\                               MD, 36.11 \[5.52, 66.70\]\       
                           2) 6MWD\                                MD, -1.20 \[-1.39, -1.01\]\      
                           3) Borg scale questionnaire\            MD, 6.10 \[4.95, 7.25\]\         
                           4) Arterial blood gas\                  MD, -1.53 \[-1.94, -1.12\]\      
                           SaO~2~\                                 MD, -0.24 \[-0.73, 0.25\]\       
                           5) Syndrome score of TCM\               MD, -1.51 \[-1.95, -1.07\]\      
                           Fatigue\                                MD, -1.35 \[-1.59, -1.11\]\      
                           Wheezing\                               MD, -1.63 \[-2.04, -1.22\]       
                           Cough\                                                                   
                           Coated tongue\                                                           
                           Pulse manifestation                                                      

  Yang QM 2018 ([@B51])    1\) Clinical efficacy\                  OR, 4.86 \[1.76, 13.39\]\        n.r.
                           Total effective rate\                   MD, 29.05 \[26.14, 31.96\]\      
                           2) 6MWD\                                MD, -1.78 \[-2.32, -1.24\]       
                           4) Syndrome score of TCM\                                                
                           Total syndrome score                                                     

  Ma Q 2018 ([@B28])       1\) Clinical efficacy\                  OR, 3.75 \[1.31, 10.72\]\        No adverse reactions
                           Total effective rate\                   OR, 3.12 \[1.13, 8.60\]\         
                           TCM syndrome effective\                 MD, 4.34 \[3.15, 5.53\]\         
                           2) Pulmonary function tests\            MD, 0.27 \[-0.02, 0.56\]\        
                           DLCO\                                   MD, -0.07 \[-0.34, 0.20\]\       
                           TLC\                                    MD, -1.03 \[-2.01, -0.05\]\      
                           VC\                                     MD, 3.80 \[1.06, 6.54\]\         
                           3) Arterial blood gas\                  MD, -0.33 \[-0.80, 0.14\]\       
                           SaO~2~\                                 MD, -1.66 \[-2.16, -1.16\]\      
                           4) Syndrome score of TCM\               MD, -0.20 \[-0.53, 0.13\]\       
                           Total syndrome score\                   MD, 0.03 \[-0.32, 0.38\]\        
                           Short of breath\                        MD, -0.91 \[-1.10, -0.72\]\      
                           Wheezing\                               MD, -0.40 \[-0.75, -0.05\]\      
                           Cough\                                  MD, -0.07 \[-0.45, 0.31\]\       
                           Phlegm\                                 MD, 0.37 \[-0.08, 0.82\]\        
                           Cyanosis\                               Inaccurate data\                 
                           Clubbed-finger\                         MD, 0.12 \[-0.21, 0.45\]         
                           Velcro rale\                                                             
                           5) HRCT score\                                                           
                           6) mMRC dyspnea scale\                                                   
                           7) 6MWD scores                                                           

  Deng F 2018 ([@B7])      1\) Clinical efficacy\                  OR, 2.59 \[1.12, 6.02\]\         n.r.
                           Total effective rate\                   MD, 2.99 \[0.23, 5.75\]\         
                           2) Pulmonary function tests\            MD, 3.63 \[1.09, 6.17\]\         
                           FVC% pred\                              MD, 6.67 \[3.72, 9.62\]\         
                           DLCO% pred\                             MD, -0.24 \[-0.35, -0.13\]\      
                           4) Arterial blood gas\                  MD, -1.32 \[-1.84, -0.80\]       
                           PaO2\                                                                    
                           5) BALF\                                                                 
                           IGF-1\                                                                   
                           IGFBP-4                                                                  

  Guo SJ 2019 ([@B12])     1\) Clinical efficacy\                  OR, 8.54 \[3.40, 21.50\]\        No adverse reactions
                           Total effective rate\                   OR, 8.54 \[3.40, 21.50\]\        
                           TCM syndrome effective\                 MD, 0.43 \[0.28, 0.58\]\         
                           2) Pulmonary function tests\            MD, 6.18 \[1.41, 10.95\]\        
                           FVC\                                    MD, 2.88 \[2.00, 3.76\]\         
                           FVC% pred\                              MD, 16.97 \[13.44, 20.50\]\      
                           DLCO\                                   MD, 0.54 \[0.45, 0.63\]\         
                           DLCO% pred\                             MD, -34.00 \[-38.72, -29.28\]\   
                           ΔFVC\                                   MD, -25.00 \[-30.26, -19.74\]\   
                           3) SGRQ scores\                         MD, 1.00 \[-3.25, 5.25\]\        
                           Total scores\                           MD, -35.00 \[-37.93, -32.07\]\   
                           Symptoms scores\                        MD, -14.82 \[-15.78, -13.86\]    
                           Activity limitation scores\                                              
                           Impact scores\                                                           
                           4) Syndrome score of TCM\                                                
                           Total syndrome score                                                     

  Peng YF 2019 ([@B35])    1\) Clinical efficacy\                  OR, 1.66 \[0.41, 6.78\]\         Experimental:\
                           Total effective rate\                   MD, -4.22\[-13.62, 5.18\]\       Itch of skin (n= 1)\
                           2) Pulmonary function tests\            MD, 1.15\[-5.82, 8.12\]\         Nausea (n= 1)\
                           DLCO% pred\                             MD, 32.40 \[1.49, 63.31\]\       Control:\
                           VC% pred\                               MD, -4.08 \[-6.57, -1.59\]\      Itch of skin (n= 2)\
                           4) 6MWD\                                MD, 0.89 \[-5.43, 7.21\]\        Nausea (n= 2)\
                           5) SGRQ scores\                         MD, 2.65 \[1.15, 4.15\]\         Erythra (n= 1)
                           Total scores\                           MD, -2.60 \[-4.32, -0.88\]\      
                           3) Arterial blood gas\                  MD, -2.56 \[-4.88, -0.24\]\      
                           PaO~2~\                                 MD, -2.20 \[-4.33, -0.07\]       
                           SaO~2~\                                                                  
                           6) Serum cytokines\                                                      
                           TGF-β1\                                                                  
                           TNF-α\                                                                   
                           7) Syndrome score of TCM\                                                
                           Total syndrome score                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------

n.r.: not reported.

Meta-analysis {#s3_5}
-------------

### Clinical Efficacy {#s3_5_1}

The 15 studies ([@B42]; [@B46]; [@B41]; [@B8]; [@B50]; [@B45]; [@B4]; [@B29]; [@B57]; [@B20]; [@B7]; [@B28]; [@B51]; [@B12]; [@B35]) that compared total effective rate of clinical efficacy included a total of 1049 participants, 534 in experimental group and 515 in control group, respectively. The 15 studies had homogeneity (heterozygosity test, Chi² = 11.07, P = 0.68, I² = 0%). When the fixed effect model was used to merge OR values, the pooled OR was 4.30 (95% CI 3.31-5.90, Z = 9.04, P \< 0.00001). This indicated that total effective rate of clinical efficacy was statistically significantly higher in experimental group than control group ([**Figure 2A**](#f2){ref-type="fig"}).

![Forest plot of comparison: clinical efficacy. **(A)** Total effective rate of clinical efficacy was statistically significantly higher in experimental group than control group. **(B)** TCM syndrome effective rate of clinical efficacy was statistically significantly higher in experimental group than control group.](fphar-11-00415-g002){#f2}

The three studies ([@B50]; [@B28]; [@B12]) that compared TCM syndrome effective rate of clinical efficacy included a total of 236 participants, 118 in experimental group and 118 control group, respectively. The three studies had homogeneity (heterozygosity test, Chi² = 2.20, P = 0.33, I² = 9%). When the fixed effect model was used to merge OR values, the pooled OR was 5.77 (95% CI 3.04-10.95, Z = 5.36, P \< 0.00001). This indicated that TCM syndrome effective rate of clinical efficacy was statistically significantly higher in the experimental group than in the control group ([**Figure 2B**](#f2){ref-type="fig"}).

### Pulmonary Function Tests {#s3_5_2}

The two studies ([@B57]; [@B12]) that compared FVC included a total of 250 participants, 125 and 125 in experimental group and control group, respectively. The two studies had heterozygosity (heterozygosity test, Chi² = 4.82, P = 0.03, I² = 79%). When the random effect model was used to merge MD values, the pooled MD was 0.58 (95% CI 0.26-0.90, Z = 3.53, P = 0.0004). This indicated that FVC was statistically significantly higher in the experimental group than in the control group ([**Figure 3A**](#f3){ref-type="fig"}).

![Forest plot of comparison: pulmonary function tests. **(A)** FVC was statistically significantly higher in experimental group than control group. **(B)** FVC% pred was statistically significantly higher in experimental group than control group. **(C)** TLC% pred was statistically significantly higher in experimental group than control group. **(D)** DLCO was statistically significantly higher in experimental group than control group. **(E)** DLCO% pred was statistically significantly higher in experimental group than control group.](fphar-11-00415-g003){#f3}

The five studies ([@B8]; [@B48]; [@B29]; [@B7]; [@B12]) that compared FVC% pred included a total of 459 participants, 231 in experimental group and 228 control group, respectively. The five studies had heterozygosity (heterozygosity test, Chi² = 11.30, P = 0.02, I² = 65%). When the random effect model was used to merge MD values, the pooled MD was 6.23 (95% CI 3.73-8.74, Z = 4.88, P \< 0.00001). This indicated that FVC% pred was statistically significantly higher in experimental group than control group ([**Figure 3B**](#f3){ref-type="fig"}).

The two studies ([@B42]; [@B4]) that compared TLC% pred included a total of 88 participants, 45 and 43 in experimental group and control group, respectively. The two studies had homogeneity (heterozygosity test, Chi² = 0.93, P = 0.33, I² = 0%). When the fixed effect model was used to merge MD values, the pooled MD was 5.90 (95% CI 1.56-10.24, Z = 2.66, P = 0.008). This indicated that TLC% pred was statistically significantly higher in experimental group than control group ([**Figure 3C**](#f3){ref-type="fig"}).

The four studies ([@B46]; [@B57]; [@B28]; [@B12]) that compared DLCO included a total of 370 participants, 194 and 176 in experimental group and control group, respectively. The four studies had heterozygosity (heterozygosity test, Chi² = 93.83, P \< 0.00001, I² = 97%). When the random effect model was used to merge MD values, the pooled MD was 3.18 (95% CI 1.13-5.24, Z = 3.04, P = 0.002). This indicated that DLCO was statistically significantly higher in the experimental group than control group ([**Figure 3D**](#f3){ref-type="fig"}).

The seven studies ([@B42]; [@B8]; [@B4]; [@B48]; [@B7]; [@B12]; [@B35]) that compared DLCO% pred included a total of 523 participants, 263 and 260 in experimental group and control group, respectively. The seven studies had heterozygosity (heterozygosity test, Chi² = 48.44, P \< 0.00001, I² = 88%). When the random effect model was used to merge MD values, the pooled MD was 6.27 (95% CI 1.98-10.56, Z = 2.87, P = 0.004). This indicated that DLCO% pred was statistically significantly higher in experimental group than control group ([**Figure 3E**](#f3){ref-type="fig"}).

### 6MWD {#s3_5_3}

The five studies ([@B29]; [@B20]; [@B30]; [@B51]; [@B35]) that compared 6MWD included a total of 366 participants, 184 and 182 in experimental group and control group, respectively. The five studies had homogeneity (heterozygosity test, Chi² = 0.50, P = 0.97, I² = 0%). When the fixed effect model was used to merge MD values, the pooled md was 29.47 (95% CI 27.85-31.09, Z = 35.68, P \< 0.00001). This indicated that 6MWD was statistically significantly higher in experimental group than control group ([**Figure 4**](#f4){ref-type="fig"}).

![Forest plot of comparison: 6MWD. 6MWD was statistically significantly higher in experimental group than control group.](fphar-11-00415-g004){#f4}

### Questionnaire Score {#s3_5_4}

The four studies ([@B41]; [@B48]; [@B12]; [@B35]) that compared total score of SGRQ score included a total of 276 participants, 139 and 137 in experimental group and control group, respectively. The four studies had heterozygosity (heterozygosity test, Chi² = 121.97, P \< 0.00001, I² = 98%). When the random effect model was used to merge MD values, the pooled MD was -13.39 \[95% CI (-28.97)-(2.19), Z = 1.68, P = 0.09\]. This indicated that there was no significant difference between experimental group and control group ([**Figure 5A**](#f5){ref-type="fig"}).

![Forest plot of comparison: questionnaire score. **(A)** Comparing total score of SGRQ score, there was no significant difference between experimental group and control group. **(B)** Symptoms score of SGRQ score was statistically significantly lower in experimental group than control group. **(C)** Comparing activity limitation score of SGRQ score, there was no significant difference between experimental group and control group. **(D)** Comparing impact score of SGRQ score, there was no significant difference between experimental group and control group. **(E)** Borg scale questionnaire score was statistically significantly lower in experimental group and control group.](fphar-11-00415-g005){#f5}

The three studies ([@B41]; [@B48]; [@B12]) that compared symptoms score of SGRQ score included a total of 226 participants, 114 and 112 in experimental group and control group, respectively. The three studies had heterozygosity (heterozygosity test, Chi² = 21.59, P \< 0.0001, I² = 91%). When the random effect model was used to merge MD values, the pooled MD was -14.22 \[95% CI (-25.84)- (-2.60), Z = 2.40, P = 0.02\]. This indicated that symptoms score of SGRQ score was statistically significantly lower in experimental group than control group ([**Figure 5B**](#f5){ref-type="fig"}).

The three studies ([@B41]; [@B48]; [@B12]) that compared activity limitation score of SGRQ score included a total of 226 participants, 114 and 112 in experimental group and control group, respectively. The three studies had heterozygosity (heterozygosity test, Chi² = 13.94, P = 0.0009, I² = 86%). When the random effect model was used to merge MD values, the pooled MD was -5.26 \[95% CI (-14.55)-(4.03), Z = 1.11, P = 0.27\]. This indicated that there was no significant difference between experimental group and control group ([**Figure 5C**](#f5){ref-type="fig"})

The three studies ([@B41]; [@B48]; [@B12]) that compared impact score of SGRQ score included a total of 226 participants, 114 and 112 in experimental group and control group, respectively. The three studies had heterozygosity (heterozygosity test, Chi² = 159.37, P \< 0.00001, I² = 99%). When the random effect model was used to merge MD values, the pooled MD was -13.11 \[95% CI (-40.23)-(14.02), Z = 0.95, P = 0.34\]. This indicated that there was no significant difference between experimental group and control group ([**Figure 5D**](#f5){ref-type="fig"}).

The two studies ([@B29]; [@B30]) that compared Borg scale questionnaire score included a total of 154 participants, 78 and 76 in experimental group and control group, respectively. The two studies had heterozygosity (heterozygosity test, Chi² = 6.10, P = 0.01, I² = 84%). When the random effect model was used to merge MD values, the pooled md was -0.96 \[95% CI (-1.48)-(-0.43), Z = 3.56, P = 0.0004\]. This indicated that Borg scale questionnaire score was statistically significantly lower in experimental group than control group ([**Figure 5E**](#f5){ref-type="fig"}).

### Adverse Reactions {#s3_5_5}

The seven studies ([@B42]; [@B46]; [@B50]; [@B29]; [@B28]; [@B12]; [@B35]) that compared incidence of adverse reactions included a total of 474 participants, 247 and 227 in experimental group and control group, respectively. The seven studies had homogeneity (heterozygosity test, Chi² = 0.72, P = 0.87, I² = 0%). When the fixed effect model was used to merge OR values, the pooled OR was 0.20 (95% CI 0.06-0.62, Z = 2.78, P = 0.005). This indicated that incidence of adverse reactions was statistically significantly lower in experimental group than control group ([**Figure 6**](#f6){ref-type="fig"}).

![Forest plot of comparison: adverse reactions. Incidence of adverse reactions was statistically significantly lower in experimental group than control group.](fphar-11-00415-g006){#f6}

### Publication Bias Analysis {#s3_5_6}

The publication bias was analyzed by funnel plots, which was drawn with the OR value of each outcome as the horizontal coordinate and SE (log \[OR\]) as the longitudinal coordinates. The funnel plots showed a basically inverted and symmetrical funnel shape. The results showed that there is no obvious publication bias. Funnel plots of total effective rate of clinical efficacy was shown in [**Figure 7**](#f7){ref-type="fig"}.

![Funnel plots of total effective rate of clinical efficacy. The funnel plots showed a basically inverted and symmetrical funnel shape. The results showed that there is no obvious publication bias.](fphar-11-00415-g007){#f7}

Discussion {#s4}
==========

IPF is a kind of interstitial lung disease characterized as chronic, progressive and fibrosis ([@B1]). IPF cannot be cured at present. The purpose of treatment is to delay disease progress, improve quality of life and prolong survival ([@B3]). IPF has poor prognosis, median survival time after diagnosis is about 2 to 3 years. Pulmonary function (FVC, TLC, DLCO), PaO~2~, SGRQ score, 6MWD and cough, dyspnea symptoms are highly correlated with prognosis which are independent risk factors for IPF death ([@B22]; [@B21]; [@B31]). IPF has fewer drug options, clinical guidelines have made it clear that glucocorticoids and N-acetylcystine are not recommended or used as appropriate ([@B36]; [@B11]), while pirfenidone and nintedanib have certain curative effect in the treatment of IPF, but due to the high price and some side effects, they are restricted in patient use ([@B33]; [@B23]; [@B39]). In recent years, the position of TCM in the treatment of IPF is becoming more and more important, and the clinical research and meta-analysis have shown that the herbal medicine treating IPF could improve the clinical symptoms, delay the reduction of the lung function, improve the quality of life of the patients ([@B53]; [@B6]; [@B49]).

DangGuiBuXue Decoction is composed of RA and RAS, which has the effect of replenishing qi and generating blood. It has a history of nearly 800 years. The prescription reuses RA to replenish the qi of spleen and lung to generate the source of blood, with RAS to benefit blood and camp. Experiment studies have shown that DangGuiBuXue Decoction has a good therapeutic effect on hepatic fibrosis in rabbits ([@B44]), has antifibrotic effects on adriamycin-induced nephropathy in rats ([@B47]) and has antifibrosis effects on bleomycin-induced pulmonary fibrosis in rats ([@B9]; [@B10]; [@B56]).

At present, the prescription of TCM in the treatment of IPF based on the association rules of the literature shows that the treatment of IPF with TCM is mainly related to benefiting vital energy and promoting blood circulation, among which RA and RAS are the most common herbs for invigorating qi and activating blood ([@B38]; [@B17]). There are many experiments on the treatment of IPF, which manifest RA and RAS can improve pulmonary fibrosis in animal model ([@B27]; [@B24]). Our recent research shows that RA and RAS should play an effective role in the treatment of IPF through multiple targets and multiple pathways ([@B55]).

Currently, the main study end point of IPF is the absolute value of FVC, and the secondary study end point is quality of life score and 6MWD ([@B33]; [@B23]; [@B39]). We analyzed these indicators primarily. In this study, the RCTs of RA and RAS in the treatment of IPF were systematically evaluated and meta-analysis was carried out. The results of meta-analysis show that total effective rate and TCM syndrome effective rate were statistically significantly higher in experimental group than control group, which suggest that RA and RAS can significantly improve the curative effect of IPF; FVC, FVC% pred, TCL% pred, DLCO and DLCO% pred, were statistically significantly higher in experimental group than control group, which suggest that RA and RAS is beneficial to pulmonary function of patients with IPF; 6MWD was statistically significantly higher in experimental group than control group and Borg scale questionnaire score was statistically significantly lower in experimental group than control group, which suggest that RA and RAS can improve exercise tolerance in patients with IPF; there was no significant difference between experimental group and control group compared total SGRQ scores, activity limitation scores and impact scores, but symptoms scores of SGRQ scores was statistically significantly lower in experimental group than control group, which suggest that RA and RAS can improve respiratory symptoms in patients with IPF, and other indexes may have more influencing factors.

We have also conducted a meta-analysis of other indicators. PaO~2~ were statistically significantly higher in experimental group than control group, which suggest that RA and RAS can improve the oxygenation in patients with IPF and there was no significant difference between experimental group than control group compared SaO~2~, which may be related to the characteristics of the oxygen dissociation curve ([**Figure S3**](#SM1){ref-type="supplementary-material"}). TNF-α was statistically significantly lower in experimental group than control group and there was no significant difference between experimental group than control group compared TGF-β1, which suggest that inhibitory inflammatory factors may play a role of RA and RAS in the treatment of IPF, but more samples are needed to further verify it ([**Figure S4**](#SM1){ref-type="supplementary-material"}).

In this systematic evaluation, the TCM syndrome effective rate and syndrome score of TCM were analyzed and made meta-analysis. The results of meta-analysis showed that TCM syndrome effective rate of clinical effect was statistically significantly higher in experimental group than control group; cough, wheezing, short of breath, fatigue, thirst, coated tongue and pulse manifestation syndrome score of TCM were statistically significantly lower in experimental group than control group. These results suggest that RA and RAS is effective in treating IPF, especially could improve the syndrome of cough, wheezing, short of breath and other syndrome which are closely related to the respiratory system ([**Figure S5**](#SM1){ref-type="supplementary-material"}).

It has been reported that TCM has potential hepatotoxicity ([@B43]; [@B34]). We also analyzed adverse reactions of include studies. Incidence of adverse reactions was statistically significantly lower in experimental group than control group, which suggest that the clinical application of RA and RAS in the treatment of IPF is safe. And there was no significant potential hepatotoxicity of RA and RAS in the treatment of IPF. Interestingly, elevated aminotransferase occurred in the control group. It is speculated that the dialectical use of TCM may reduce the toxicity and side effects of western drugs such as prednisone.

However, there are some limitations in this systematic evaluation. First of all, the study of only using RA and RAS in the treatment group is less, and we included the studies using RA and RAS as the main component in experimental group. The role of other traditional herbal medicine will have a certain impact on the results, but the role of RA and RAS as the main component is still of great significance. The next step of our research is to carry out a comparative RCT of long-term treatment of RA and RAS only in IPF. In view of the clinical particularity of TCM, and in accordance with the characteristics of real world situation, we believe that in our future read world clinical research, the experimental group should also be allowed to take other drugs, including other herbal medicine, on the basis of adhering to the rules of using RA and RAS. Secondly, some of the random methods are not clear; most of the studies do not introduce allocation concealment; most of the studies do not introduce blindness; two studies had inaccurate outcome data; and all studies were unable to know if there were selective reports. Although the quality of some research methods is low, we carefully evaluate the literature to ensure that the results are true and credible. Lastly, the treatment methods were not uniform, the dosage of RA and RAS was not the same, and the drugs in the control group were also different. Some of the research treatment cycles were short, and the safety of long-term combination of RA and RAS in the treatment of IPF could not be accurately evaluated. The existence of these biases may affect the accuracy of the research conclusions. However, our research is mainly to study the use of RA and RAS in IPF patients, so there is no special regulation on the dose and the included studies were RCTs and the diagnostic criteria was consistent, the baselines for inclusion in the literature do not differ significantly. All the prescriptions in included studies were prepared according to Chinese pharmacopeia by experts and famous old Chinese medicine practitioners and there have been many high performance liquid chromatography (HPLC) studies on RA and RAS in the past ([@B26]; [@B25]; [@B52]).

Conclusions {#s5}
===========

To sum up, RA and RAS are effective and safe in the treatment of IPF, which is beneficial to pulmonary function and exercise tolerance of these patients. Because the quality of the study is low, the quantity and sample size are small, and more high quality, multi-center, large sample RTCs are needed to obtain better evidence.
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